Want to see TSE:EDT full AI Analyst Report?
Spectral Medical (EDT) AI Stock Analysis
Top Page
Spectral Medical
(TSX:EDT)
The score is driven primarily by very weak financial performance—tiny and declining revenue, extremely large losses, persistent cash burn, and a highly stressed balance sheet with negative equity and rising debt. Technicals add further pressure with a clear downtrend and negative momentum, despite oversold readings. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Spectral Medical (EDT) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 215.76M
- Dividend Yield
- ―
- Average Volume (3M)
- 57.07K
- Price to Earnings (P/E)
- -8.0
- Beta (1Y)
- 0.92
- Revenue Growth
- 1.46%
- EPS Growth
- -64.85%
- Country
- Canada
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Spectral Medical Business Overview & Revenue Model
Company Description
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro dia...
How the Company Makes Money
Spectral Medical’s primary economic model is typical of a clinical-stage medtech/biotech company: it seeks to generate future revenue by developing, clinically validating, and commercializing proprietary critical-care products (therapeutic devices an...
Spectral Medical Financial Statement Overview
Summary
Very weak fundamentals: TTM revenue is small (~$2.6M) and declined (~-7%) with an inconsistent growth profile. Profitability is severely negative (deep gross losses; TTM net margin roughly -1,392%). Financial risk is elevated with negative stockholders’ equity (~-$70M) and rising debt (~$25.7M) against a thin asset base (~$3.2M). Cash burn remains significant (TTM operating and free cash flow both about -$10.5M), implying ongoing external funding needs.
Income Statement
8Very NegativeBalance Sheet
6Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.57M | 2.44M | 2.29M | 1.60M | 1.67M | 2.00M |
| Gross Profit | -2.44M | -5.16M | 1.02M | 662.00K | 983.00K | 1.16M |
| EBITDA | -32.39M | -42.27M | -11.97M | -13.96M | -7.18M | -6.38M |
| Net Income | -35.76M | -47.69M | -15.40M | -15.66M | -11.28M | -8.79M |
Balance Sheet | ||||||
| Total Assets | 3.19M | 6.10M | 5.32M | 5.21M | 12.00M | 11.55M |
| Cash, Cash Equivalents and Short-Term Investments | 803.00K | 4.07M | 2.99M | 2.95M | 8.41M | 8.89M |
| Total Debt | 25.68M | 21.09M | 14.93M | 8.56M | 7.57M | 582.00K |
| Total Liabilities | 73.26M | 75.82M | 32.87M | 21.76M | 14.55M | 7.47M |
| Stockholders Equity | -70.07M | -69.72M | -27.55M | -16.55M | -2.55M | 4.08M |
Cash Flow | ||||||
| Free Cash Flow | -10.49M | -9.72M | -8.85M | -10.91M | -9.93M | -9.18M |
| Operating Cash Flow | -10.46M | -9.52M | -8.82M | -10.72M | -9.90M | -8.70M |
| Investing Cash Flow | -28.00K | -195.00K | -27.00K | -185.00K | -33.00K | -325.00K |
| Financing Cash Flow | 8.19M | 12.91M | 8.88M | 5.44M | 9.46M | 12.16M |
Spectral Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EDT, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.17, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 44.69 is Neutral, neither overbought nor oversold. The STOCH value of 28.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:EDT.
Spectral Medical Peers Comparison
Overall Rating
TSE:CPH74Outperform
TSE:PRN50Neutral- TSE:EDT42Neutral
TSE:SONA40.5Neutral
TSE:BUX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:CPH | 74Outperform | CAD 331.67M | 8.19 | 22.74% | ― | 3.18% | 140.09% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:PRN | 50Neutral | CAD 335.37M | -6.77 | -62.45% | ― | 59.60% | 32.53% |
| TSE:EDT | 42Neutral | CAD 303.48M | -8.01 | 51.23% | ― | 1.46% | -64.85% |
| TSE:SONA | 41Neutral | CAD 34.38M | -13.08 | 448.05% | ― | ― | 24.65% |
| TSE:BUX | 40Underperform | CAD 50.05M | -34.81 | -250.77% | ― | -82.05% | 23.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:EDT | Spectral Medical (Edtxf) | 1.03 | -0.44 | -29.93% | |
| TSE:CPH | Cipher Pharmaceuticals Inc | 13.05 | -1.69 | -11.47% | |
| TSE:BUX | BioMark Diagnostics | 0.47 | 0.13 | 38.24% | |
| TSE:PRN | Profound Medical | 9.18 | 0.91 | 11.00% | |
| TSE:SONA | Sona Nanotech, Inc | 0.28 | -0.33 | -54.10% |
Spectral Medical Corporate Events
Spectral Medical Hits Regulatory Milestone on PMX as Financing and Commercial Plans Advance
PositiveSpectral Medical reported that the second quarter of 2026 marked a key inflection point as it submitted and successfully filed its Premarket Approval application with the U.S. Food and Drug Administration for PMX, its targeted therapy for endotoxic s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026